Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database
- 1 January 2015
- journal article
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 99 (1) , 200-208
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Management of Clinical Stage IIIA Primary Lung Cancers in the National Cancer DatabaseThe Annals of Thoracic Surgery, 2014
- Improved Survival Associated with Neoadjuvant Chemoradiation in Patients with Clinical Stage IIIA(N2) Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2013
- Treatment of Stage III Non-small Cell Lung CancerChest, 2013
- Methods for Staging Non-small Cell Lung CancerChest, 2013
- Comparison of Cases Captured in the National Cancer Data Base with Those in Population-based Central Cancer RegistriesAnnals of Surgical Oncology, 2013
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming Seventh Edition of the TNM Classification for Lung CancerJournal of Thoracic Oncology, 2007
- Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2003
- A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 1994
- A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung CancerNew England Journal of Medicine, 1994